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SUMMARY – Hereditary angioedema (HAE) is a rare autosomal dominant disease with defi-
ciency (type I) or dysfunction (type II) of C1 inhibitor, caused by mutations in the C1-INH gene, 
characterized by recurrent submucosal or subcutaneous edemas including skin swelling, abdominal 
pain and life-threatening episodes of upper airway obstruction. The aim of this study was to investi-
gate healthcare experiences in children with HAE due to C1 inhibitor deficiency (C1-INH-HAE) in 
Croatia in order to estimate the number of affected children and to recommend management proto-
cols for diagnosis, short-term prophylaxis and acute treatment. Patients were recruited during a 4-year 
period at five hospitals in Croatia. Complement testing was performed in patients with a positive 
family history. This pilot study revealed nine pediatric patients positive for C1-INH- HAE type I, 
aged 1-16 years, four of them asymptomatic. Before the age of one year, C1-INH levels may be lower 
than in adults; it is advisable to confirm C1-INH-HAE after the age of one year. Plasma-derived C1-
INH is recommended as acute and short-term prophylactic treatment. Recombinant C1-INH and 
icatibant are licensed for the acute treatment of pediatric patients. In Croatia, HAE is still underdiag-
nosed in pediatric population.
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Introduction
Hereditary angioedema (HAE) due to C1 inhibi-
tor deficiency (C1-INH-HAE) is a rare autosomal 
dominant disease with deficiency (type I C1-INH- 
-HAE) or dysfunction (type II C1-INH-HAE) of 
C1 inhibitor (C1-INH) due to mutations in the 
SERPING1 gene1-3. In some patients with a normal 
level of C1-INH, angioedema is related to mutation 
in coagulation factor XII gene (HAE-FXII), plas-
minogen (HAE-PLG) and angiopoetin-1 (HAE- 
-ANGPT1), or the cause of angioedema remains 
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 unknown (U-HAE)2,4. All types of the disease share 
the same clinical presentation due to unregulated gen-
eration of bradykinin causing leakage of plasma from 
postcapillary venules5-7. Clinical events in the popula-
tion with C1-INH-HAE are characterized by recur-
rent submucosal or subcutaneous edemas including 
skin swelling, abdominal pain and life-threatening 
episodes of upper airway obstruction. Attacks may oc-
cur at any age after birth but early onset of symptoms 
may predict a more severe course of the disease, which 
worsens in puberty8. The most common attack triggers 
include mechanical trauma, stress and infections9,10. 
Also, dental-oral procedures, endoscopies or opera-
tions in general anesthesia with intubation can pre-
cipitate angioedema. If not treated, edema may persist 
for 1 to 5 days before resolving spontaneously11. The 
earliest and the most common swelling site in pediat-
ric population is subcutaneous edema of the extremi-
ties. Upper airway edema is more severe in small chil-
dren causing death by asphyxiation12,13. Abdominal 
pain, vomiting and diarrhea, frequent in general pedi-
atric population, are present in 80%-90% of HAE pa-
tients8. Edema can also affect genitalia, urinary blad-
der, muscles, joints, or can cause migraine or visual 
disturbances and headache8. The aim of this study was 
to investigate health care experiences in children with 
HAE in Croatia in order to estimate the number of 
affected children and to recommend management 
protocols for establishing HAE diagnosis, short- term 
prophylaxis before triggering procedures, and acute 
treatment of pediatric patients.
Patients and Methods
Patients
The patients were recruited during a 4-year period 
(2012-2016) at five hospitals in Zagreb, Šibenik and 
Split, Croatia. The diagnosis of C1-INH-HAE was 
established based on complement testing (comple-
ment C4 and C1 inhibitor antigenic levels) and char-
acteristic clinical features such as upper airway and 
subcutaneous swelling or abdominal pain14. It was per-
formed in nine patients from 18 families with con-
firmed C1-INH-HAE type I diagnosis. A question-
naire (Appendix), developed in line with the interna-
tional consensus algorithm, was sent to each center, in 
order to explore patient experiences of the disease, in-
cluding diagnosis and treatment2.
The study was approved by the participating hospi-
tal ethics committees and a parental written consent 
was granted.
Complement testing
Serum protein concentrations of C1 inhibitor 
(normal range: 0.20-0.35 g/L) and C4 (normal range: 
0.16-0.31 g/L) were quantified using radial immuno-
diffusion (Siemens, Marburg, Germany). C1 inhibitor 
function was measured using an enzyme immunoassay 
(Quidel Corporation, California, USA) considering 
C1 inhibitor functional levels ≤40% of normal value as 
decreased levels. All measurements were performed in 
accordance with the manufacturer’s instructions.
Statistical analysis
No formal statistical hypothesis was tested. Statis-
tical analysis was essentially descriptive (percentages).
Results
Our pilot study identified nine children with HAE 
with positive family history, aged 0-16 years. All of 
them tested positive for C1-INH-HAE type I; four of 
them were asymptomatic (patient 1, age 8; patient 3 
age 15; patient 6, age 6; and patient 9, age 1) (Table 1). 
Detailed clinical data and complement measurements 
are outlined in Table 1. There were six female (F) and 
three male (M) patients. Age at onset of symptoms 
ranged from 1 to 15 years. The prime localization of 
the attacks was peripheral edema in 55% (5 patients = 
3 F, ages 6, 8 and 16; and 2 M, ages 4 and 10), followed 
by facial swelling in 33% (3 patients = 2 F, ages 16 and 
6; and 1 M, age 16), and laryngeal (1 M, age 16) and 
abdominal edema (1 F, age 6) in one patient (12%) 
each. Abdominal pain as a symptom of HAE was the 
prime localization of attacks in patient 8. In patient 2 
with facial and neck edema, dental procedures precipi-
tated facial and laryngeal attacks. Presentation of C1-
INH-HAE in the upper airways was detected in pa-
tient 4. This study identified three adolescents.
Plasma-derived C1-INH (pdC1-INH, human) 
was administered as acute treatment in the patient 
with laryngeal, facial and neck edema (20 IU per kg 
body weight by intravenous injection).
In this study, C1-INH-HAE was diagnosed before 
or immediately after symptom onset.
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Discussion
Using an estimated prevalence of 1:50 000 and na-
tional census statistics of 896 605 children aged 19 
years or less in Croatia, approximately 18 children 
would be expected to have this disease15. In this study, 
we detected nine children with C1-INH-HAE type I 
from 18 families with positive family history; one of 
them (patient 4) was the first family member with es-
tablished proper C1-INH-HAE diagnosis. HAE is a 
life-altering and chronic disease. This investigation 
emphasized the variety of clinical presentation of the 
disease and possible delay in reaching an accurate di-
agnosis due to that variety. C1-INH-HAE type I di-
agnosis is corroborated with low levels of serum pro-
tein concentrations of C1-INH and C4, and type II 
with low level of C4 and normal or above normal level 
of ineffective C1-INH. The diagnosis can be further 
supported by genetic testing. All neonates/infants with 
an affected C1-INH-HAE family member should be 
screened for C1-INH deficiency; genetic testing is in-
dicated under the age of one year14. Genetic testing is 
also indicated for HAE-FXII, HAE-PLG and HAE-
ANGPT1 while U-HAE diagnosis can be established 
with positive family history and typical clinical pre-
sentation.
Complement testing is available in clinical centres 
throughout Croatia, while genetic testing can be per-
formed in collaboration with the University Clinic of 
Pulmonary and Allergic Diseases Golnik, Slovenia, in 
agreement with the Croatian Health Insurance Fund10.
Abdominal pain commonly occurs in the general 
pediatric population. Differential diagnosis can be dif-
ficult as abdominal pain is common in pediatric C1-
INH-HAE population, as recorded in patient 814. 
HAE is often underdiagnosed or misdiagnosed as a 
cause of abdominal pain. During abdominal edema at-
tack, HAE patients are usually observed as cases of 
gastroenterocolitis or acute abdomen, or may undergo 
unnecessary surgical procedures16. Ultrasound findings 
of abdominal fluid and bowel swelling can help dif-
ferentiate patients with HAE17. C1-INH-HAE diag-
nosis should be early established and also considered 
in patients experiencing recurrent angioedema with 
poor response to epinephrine, glucocorticoids and an-
tihistamines, since they are ineffective in C1-INH-
HAE1,18-20. Some children may develop prodromal 
nonpruritic rash, erythema marginatum, but urticaria 
with itching at any age practically excludes HAE diag-
nosis8,20.
Puberty and oral hormonal contraceptives
Puberty can aggravate the symptoms of HAE, par-
ticularly in females, triggered by menstruation and 
ovulation9. Estrogen-containing medications for acne 



































































































1 F 8 Asympt + 0.05 0.05 36
2 F 16 15 + + - - + 0.05 <0.05 30
3 F 15 Asympt + 0.05 0.05 17
4 M 16 6 + + - + + 0.06 0.05 20
5 F 8 3 + - - - + 0.15 0.09 33
6 M 6 Asympt + <0.05 0.06 24
7 M 4 1 + - - - + 0.11 0.13 56
8 F 6 3 + + + - + 0.07 0.05 33
9 F 1 Asympt + <0.05 0.15 48
Asympt = asymptomatic; M = male; F = female; C1-INH = C1 inhibitor
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or oral contraceptives can precipitate attacks, so they 
are not recommended in patients with HAE14.
Medical procedures and HAE
Physicians can trigger an HAE attack with their 
procedures. Dental procedures can precipitate facial 
and laryngeal attacks, as it was the case in patient 2 
with facial and neck edema13. Presentation of C1-
INH-HAE in the upper airways, as in patient 4, may 
lead to asphyxiation, the time from symptom onset to 
asphyxiation varying from as little as 20 minutes to as 
long as 30 hours, making tracheotomy a lifesaving 
treatment13,21. Education of patients, parents and child 
care workers about laryngeal symptoms that may lead 
to asphyxiation, such as hoarseness, lump in the throat 
or shortness of breath, is crucial. Endoscopy proce-
dures or operations in general anesthesia with intuba-
tion that are common in pediatric population, such as 
adenotonsillectomy or appendectomy, might lead to 
laryngeal edema or painful abdominal edema. PdC1-
INH is recommended as a short-term prophylactic 
treatment 1-2 hours before triggering procedures at a 
dose of 20 IU per kg body weight by intravenous injec-
tion14. If pdC1-INH is not available, attenuated oral 
androgen danazol 5 mg/kg/day or 10 mL/kg solvent 
detergent plasma (SDP) can be administered14. Pro-
phylaxis with danazol should start 5 days before and be 
continued for 2 days postprocedure. Treatment with 
pdC1-INH and recombinant C1-INH (rhC1-INH) 
to replace the functionally or quantitatively deficient 
C1-INH in patients with HAE has been shown to be 
effective for treating acute edematous attacks at any 
site in children. PdC1-INH is licensed for children at 
any age in a dose of 20 IU per kg body weight and 
rhC1-INH (conestat alfa) or kallikrein inhibitor (ecal-
lantide, only in the USA) for those older than 12 
years14,22. Conestat alfa should be administrered at a 
dose of 50 IU per kg body weight by intravenous injec-
tion15. Icatibant administered in children and adoles-
cents subcutaneously based on body weight has been 
recently approved for children above the age of 2 
years15. Icatibant is approved for self-administration, 
allowing patients/families to take control of their dis-
ease. SDP is indicated in emergency situations when 
licensed therapy is not available (or fresh frozen plas-
ma (FFP) as a source of C1-INH). Individuals with 
HAE require lifelong therapy and evaluation of dis-
ease activity.
In conclusion, HAE is still underdiagnosed in pe-
diatric population. This was the first survey of pediatric 
HAE in Croatia. According to these findings, we rec-
ommend comprehensive care, not only parental or 
medical, but also of all those included in the process of 
education in schools or kindergartens23. Also, identifi-
cation card with individual treatment plan made by 
HAE specialist must be provided for each pediatric 
HAE patient. Dental-oral procedures, endoscopies or 
operations in general anesthesia can precipitate angio-
edema. Plasma-derived C1-INH is recommended as 
short-term prophylactic treatment before triggering 
procedures. Plasma-derived C1-INH, recombinant 
C1-INH (for children above 12 years) and icatibant 
(for children above 2 years) are licensed for the acute 
treatment of pediatric patients. Raising awareness 
about rare diseases among parents and physicians is 
essential for early and accurate establishment of the 
diagnosis, effective management of acute attacks and 
prior to triggering procedures in order to avoid unnec-
essary investigations and to prevent adverse events.
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Appendix
Questionnaire for patients with hereditary angioedema
UPITNIK ZA PACIJENTE S HEREDITARNIM ANGIOEDEMOM
Datum  datum rođenja 
Ime i prezime 
MOLIM PODVUĆI:
–  dob pojave bolesti:  
0-5 godina; 6-10 godina; 11-20 godina; >20 godina
–  imao/la sam:  
edem kože, bolni edem trbuha, edem grkljana, druge kliničke manifestacije
Znakovi bolesti posljednjih mjesec dana (navesti):
Uzimate li profilaksu (npr. Danazol tbl) DA NE
Ako DA navedite koju 
označiti križićem:









Išao sam na 
hitni prijam
Koliko su česte u godini dana?
Prije preventivne th/ nakon 
preventivne th





Znakovi bolesti prije započimanja preventivne terapije  
(molim navesti znakove bolesti i koliko puta godišnje su se javile):
Što Vam izaziva napade bolesti? Molim podvući
infekcija napor trauma hormonska kontracepcija
Ostalo, što 
Jeste li alergični na neki lijek? DA NE
Ako DA koji? 
Bolujete li od neke druge bolesti? DA NE
ako Da koje 
Uzimate li lijekove (navesti koje)? 
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Imate li kod sebe lijek Berinert za samopomoć? DA NE
Imate li kod sebe lijek Firazyr za samopomoć? DA NE
Jeste li ikada primijenili lijek za samopomoć? DA NE
Jeste li ikada dobili neki od navedenih lijekova na hitnom prijmu? DA NE
Jeste li ikada imali ikakvu intervenciju (intubacija, traheotomija)? DA NE
Ako DA koju intervenciju? 
Koju terapiju dobijete u akutnoj epizodi? 
Vaši nalazi:
Koncentracija C4  Koncentracija C1 inhibitora 
Imate li stečeno pomanjkanje C1 inhibitora? DA NE
Bolesni srodnici (npr. otac, sin…): 
Klinički zdravi srodnici (nemaju simptome bolesti) s laboratorijski potvrđenim manjkom C1 inh (i sniženim C4)
Srodnici koje možemo pozvati na testiranje: 
Obiteljsko stablo:
Suglasan sam s provođenjem genetske analize gena za hereditarni angioedem.
Ime i prezime  datum 
ništa jako
Koliko Vas bolest ometa u svakodnevnom životu? 1 2 3 4 5
Koliko Vas bolest ometa na poslu? 1 2 3 4 5
Jeste li kada doživjeli neugodnosti radi bolesti? 1 2 3 4 5
Smeta li Vašem partneru Vaša bolest? 1 2 3 4 5
Utječe li Vaša bolest na kvalitetu Vašeg života? 1 2 3 4 5
Utječe li Vaša bolest na kvalitetu života Vaše obitelji? 1 2 3 4 5
Jeste li član neke od udruga oboljelih od HAE? DA NE
Kako se informirate o svojoj bolesti? 
Što biste predložili kao mjeru unaprjeđenja zdravstvene skrbi ili kvalitete života za oboljele od HAE?
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Sažetak
HEREDITARNI ANGIOEDEM UZROKOVAN MANJKOM C1-INHIBITORA  
U PEDIJATRIJSKIH BOLESNIKA U HRVATSKOJ – PRVO NACIONALNO ISTRAŽIVANJE,  
DIJAGNOSTIČKI I PROFILAKTIČKI IZAZOVI
Lj. Karadža-Lapić, M. Barešić, R. Vrsalović, I. Ivković-Jureković, S. Sršen, I. Prkačin, M. Rijavec i D. Cikojević
Hereditarni angioedem (HAE) je rijetka autosomno dominantna bolest nastala zbog mutacije gena SERPING1 za inhi-
bitor plazmatskog proteina C1 (C1-INH). Uslijed manjka C1 inhibitora (tip I) ili njegove disfunkcionalnosti (tip II) dolazi 
do okidačem potaknute autoaktivacije C1-komponente komplementa i cijele kaskade koja dovodi do submukoznih ili 
subkutanih iznenadnih pojava oteklina kože, lica, kapaka, usana ili grla te abdominalnih bolova praćenih povraćanjem i 
 dehidracijom. U najtežim slučajevima uslijed edema glotisa može doći do gušenja. Cilj ovoga istraživanja bila je procjena 
ukupnog broja djece s HAE zbog nedostatka C1 inhibitora (C1-INH-HAE) u Hrvatskoj kako bi se preporučili i provodili 
ujednačeni protokoli za dijagnozu, kratkotrajnu profilaksu i akutno liječenje. Pedijatrijski bolesnici su uključivani u istraživa-
nje tijekom 4 godine u pet bolnica u Hrvatskoj. Svima s pozitivnom obiteljskom anamnezom na HAE analizirana je razina 
komplementa i C1 inhibitora. Probno istraživanje je otkrilo devet bolesnika pedijatrijske populacije u dobi od 1-16 godina 
koji su pozitivni za CI-INH-HAE tip I, od kojih su 4 bili asimptomatski. U slučaju akutnog napadaja HAE kao i za profi-
laktičnu primjenu preporuča se primjena pdC1-INH (humani inhibitor C1 esteraze). Također, rekombinantni C1-INH i 
ikatibant indicirani su za akutno liječenje pedijatrijskih bolesnika. U Hrvatskoj HAE je još uvijek nedovoljno dijagnosticiran 
u pedijatrijskoj populaciji.
Ključne riječi: Hereditarni angioedem, tipovi I i II – dijagnostika; Komplement C1 inhibitor protein, Dijete; Hrvatska
